TAO Synergies Inc. secures $11 million in a Private Equity round, backed by James Altucher and DCG, to further strategic investments in TAO tokens and the Bittensor ecosystem.
PRIVATEOct 13, 2025
Amount Raised
$11 Million
Round Type
Private Equity
New YorkBiotechnologyHealth CareArtificial IntelligenceBlockchainCryptocurrencyTherapeuticsMachine Learning
Investors
DcgJames Altucher
Description
TAO Synergies Inc. has announced a securities purchase agreement for $11 million, supported by existing stockholders, James Altucher, and new investor DCG. This financing involves the sale of Series E convertible preferred stock, convertible into common stock, along with purchase warrants. The transaction is expected to close on or about October 15, 2025, subject to customary conditions
Who to call at Synaptogenix, and when
A new round usually means Synaptogenix is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Synaptogenix raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Synaptogenix, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Synaptogenix. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Synaptogenix
Location
1185 AVENUE OF THE AMERICAS
New York, New York, United States
About
Synaptogenix is a clinical-stage biopharmaceutical company that has historically worked to develop novel therapies for neurodegenerative diseases. Synaptogenix has conducted clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer's disease. Preclinical studies have also demonstrated bryostatin's regenerative mechanisms of action for the rare disease Fragile X syndrome, and for other neurodegenerative disorders such as multiple sclerosis, stroke, and traumatic brain injury. The U.S. Food and Drug Administration has granted Orphan Drug Designation to Synaptogenix for Bryostatin-1 as a treatment for Fragile X syndrome. Bryostatin-1 has already undergone testing in more than 1,500 people in cancer studies, thus creating a large safety data base that will further inform clinical trial designs.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Synaptogenix raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
New YorkBiotechnologyHealth CareArtificial IntelligenceBlockchainCryptocurrencyTherapeuticsMachine Learning